Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

Triplet combinations containing a proteasome inhibitor are a standard of care in newly diagnosed multiple myeloma (NDMM). We examined the long-term efficacy and safety of the all-oral combination of weekly ixazomib plus lenalidomide-dexamethasone (IRd), followed by single-agent ixazomib maintenance...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Shaji Kumar, Jesús G. Berdeja, Rubén Niesvizky, Sagar Lonial, Jacob P. Laubach, Mehdi Hamadani, A. Keith Stewart, Parameswaran Hari, Vivek Roy, Robert Vescio, Jonathan L. Kaufman, Deborah Berg, Eileen Liao, S. Vincent Rajkumar, Paul G. Richardson
Format: Artigo
Sprache:Englisch
Veröffentlicht: 2019
Online-Zugang:https://doi.org/10.1038/s41375-019-0384-1
https://www.nature.com/articles/s41375-019-0384-1.pdf
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Online

https://doi.org/10.1038/s41375-019-0384-1
https://www.nature.com/articles/s41375-019-0384-1.pdf

Ähnliche Einträge